Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Shire PLC (NASDAQ:SHPG)

185.44
Delayed Data
As of Feb 23
 +4.44 / +2.45%
Today’s Change
150.06
Today|||52-Week Range
209.22
+8.84%
Year-to-Date
Biotech Movers: Shire Rises on Encouraging Angioedema Results
Feb 23 / TheStreet.com - Paid Partner Content
Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
Feb 17 / Zacks.com - Paid Partner Content
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Bioscienc...
Feb 22 / GuruFocus News - Paid Partner Content
Why Intercept Pharmaceuticals' Latest News Caused the Stock to Jump
Feb 11 / MotleyFool.com - Paid Partner Content
3 Stocks to Invest in Big Pharma
Feb 20 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close181.00
Today’s open184.19
Day’s range183.37 - 186.28
Volume1,405,663
Average volume (3 months)1,257,775
Market cap$54.6B
Dividend yield0.43%
Data as of 4:00pm ET, 02/23/2017

Growth & Valuation

Earnings growth (last year)-80.61%
Earnings growth (this year)--
Earnings growth (next 5 years)+13.39%
Revenue growth (last year)+76.71%
P/E ratio94.4
Price/Sales3.89
Price/Book1.86

Competitors

 Today’s
change
Today’s
% change
NVONovo Nordisk+0.53+1.50%
REGNRegeneron Pharmaceut...-9.26-2.50%
AZNAstraZeneca+0.59+2.04%
ABTAbbott Laboratories+0.39+0.87%
Data as of 4:02pm ET, 02/23/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)$3.52
Annual revenue (last year)$11.3B
Annual profit (last year)$325.1M
Net profit margin5.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chief Executive Officer &
Executive Director
Flemming Ornskov
Chief Financial Officer &
Executive Director
Jeffrey Poulton
Corporate headquarters
Dublin, Dublin

Forecasts


Search for Jobs